MedTrace Logo

The Added Value of a Third Supervised Training Session to a Standard 12-week Rehabilitation Program After Breast Cancer: Pilot Study

NCT05455385 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2022-07-14

No results posted yet for this study

Summary

Breast cancer is the most common type of cancer diagnosed in women. A good rehabilitation program is essential for a good recovery after breast cancer, both physically and mentally. The aim of this study is to determine if there is an added value of a third supervised training session within a standard 12-week rehabilitation program to improve physical and mental functioning after breast cancer. The investigators also want to determine the added value of hydrotherapy as a third training session within a 12-week rehabilitation program compared to a third training session with ground exercises to improve physical and mental functioning after breast cancer.

Conditions

Interventions

OTHER

standard 12-week rehabilitation program

The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.

OTHER

extra session hydrotherapy

The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.

OTHER

extra session ground exercises

The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • An De Groef, Prof · KU Leuven

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-05
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05455385 on ClinicalTrials.gov